WO2020013793A3 - Inhalation compositions comprising dopamine agonists - Google Patents

Inhalation compositions comprising dopamine agonists Download PDF

Info

Publication number
WO2020013793A3
WO2020013793A3 PCT/TR2019/050555 TR2019050555W WO2020013793A3 WO 2020013793 A3 WO2020013793 A3 WO 2020013793A3 TR 2019050555 W TR2019050555 W TR 2019050555W WO 2020013793 A3 WO2020013793 A3 WO 2020013793A3
Authority
WO
WIPO (PCT)
Prior art keywords
dopamine agonists
inhalation compositions
inhalation
compositions
lubricant
Prior art date
Application number
PCT/TR2019/050555
Other languages
French (fr)
Other versions
WO2020013793A2 (en
Inventor
Ali Turkyilmaz
Irem Yenice
Devrim Celik
Arzu CAYIR
Original Assignee
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to EP19833638.0A priority Critical patent/EP3826620A4/en
Publication of WO2020013793A2 publication Critical patent/WO2020013793A2/en
Publication of WO2020013793A3 publication Critical patent/WO2020013793A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Abstract

The invention relates to dry powder pharmaceutical compositions administered by means of inhaler devices comprising at least one dopamine agonist wherein the composition is free of lubricant and surfactant.
PCT/TR2019/050555 2018-07-12 2019-07-10 Inhalation compositions comprising dopamine agonists WO2020013793A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19833638.0A EP3826620A4 (en) 2018-07-12 2019-07-10 Inhalation compositions comprising dopamine agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2018/09930 2018-07-12
TR201809930 2018-07-12

Publications (2)

Publication Number Publication Date
WO2020013793A2 WO2020013793A2 (en) 2020-01-16
WO2020013793A3 true WO2020013793A3 (en) 2020-02-20

Family

ID=69142465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050555 WO2020013793A2 (en) 2018-07-12 2019-07-10 Inhalation compositions comprising dopamine agonists

Country Status (2)

Country Link
EP (1) EP3826620A4 (en)
WO (1) WO2020013793A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009056851A1 (en) * 2007-10-31 2009-05-07 Vectura Limited Compositions for treating parkinson's disease
WO2013109210A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising budesonide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75375C2 (en) * 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
US20120321717A1 (en) * 2003-04-14 2012-12-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009056851A1 (en) * 2007-10-31 2009-05-07 Vectura Limited Compositions for treating parkinson's disease
WO2013109210A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising budesonide

Also Published As

Publication number Publication date
EP3826620A2 (en) 2021-06-02
EP3826620A4 (en) 2023-03-08
WO2020013793A2 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
MX2020011166A (en) Cryoprotective agents for particulate formulations.
WO2015120110A3 (en) Novel pharmaceutical formulations
MX2023006856A (en) Dry powder compositions with magnesium stearate.
JP2015078230A5 (en)
WO2015160842A8 (en) Methods and formulations of capsaicinoids and capsinoids
WO2015160843A8 (en) Ion channel activators and methods of use
UY37831A (en) NEW DERIVATIVES OF QUINOLINA
MX2022013612A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies.
MY183536A (en) Pharmaceutical compositions comprising azd9291
NZ731059A (en) An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MX2021001272A (en) Bismuth-thiol compositions and methods of use.
EA201892688A1 (en) ANTIMICROBIAL COMPOSITIONS FOR LOCAL APPLICATION
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
WO2020013793A3 (en) Inhalation compositions comprising dopamine agonists
WO2020055357A3 (en) Inhalation compositions comprising phosphodiesterase-4 inhibitor
WO2016005995A3 (en) Glycol free stable liquid compositions of bendamustine
EP3400214A4 (en) Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives
WO2020055356A3 (en) Inhalation compositions comprising anti-bacterial agents
IL290927A (en) Composition used for combating metabolic diseases and uses of composition
PH12016501445A1 (en) Pharmaceutical composition including 5-{4-(aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2h)-furanone and capsule formulation including the pharmaceutical composition
WO2019104062A8 (en) Polymorphs and uses thereof
EA032385B9 (en) Pharmaceutical composition for treating gastrointestinal diseases
WO2020055359A3 (en) Oral dosage form of sorafenib tosylate
MX2019015869A (en) New oral formulations of belinostat.
EP3723727A4 (en) Pharmaceutical compositions of flurbiprofen and 5-ht1 - receptor agonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19833638

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019833638

Country of ref document: EP

Effective date: 20210212

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19833638

Country of ref document: EP

Kind code of ref document: A2